SMShehara Mendis

Shehara Mendis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shehara Mendis has a total of 160 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Concomitant Use of Proton Pump Inhibitors and Survival Outcomes in Patients Receiving Adjuvant Chemotherapy for Stage III Colon Cancer

    by Matthew Loft, Vinoja Ganeshanathan, Rachel Wong, Shehara Mendis, Matthew Croxford, Ian T. Jones, Grace Gard, Sue‐Anne McLachlan, Jeanne Tie, Lucy Gately, et al.

    Proton pump inhibitors (PPIs) are commonly prescribed in patients with cancer. Prior studies suggest concomitant PPI use may reduce the efficacy of oral capecitabine through impaired absorption, with no interaction expected with intravenous 5‐fluorouracil (5‐FU). Using the Australian Comprehensive Cancer Outcomes and Research Database (ACCORD), we identified patients with Stage III colon cancer diagnosed between 1 January 2006 and 31 December 2023. Concomitant PPI use during adjuvant chemotherapy was determined by chart review. We evaluated the prevalence of PPI use with fluoropyrimidine‐containing adjuvant therapy and its association with recurrence‐free survival (RFS) and overall survival (OS). A total of 459 patients were included as follows: 63 (14%) received 5‐FU alone, 115 (25%) capecitabine alone, 148 (32%) FOLFOX and 133 (29%) CAPOX. High‐risk disease (T4 and/or N2) was present in 203 patients (44%). Overall, 142 patients (31%) received a PPI during adjuvant chemotherapy, with similar rates across treatment groups ( p = 0.952). Formal interaction testing did not demonstrate significant heterogeneity of PPI effect across treatment regimens (RFS: LR test p = 0.615; OS: LR test p = 0.143). However, in high‐risk patients receiving CAPOX, PPI use was associated with reduced RFS (HR 3.07, 95% CI 1.38–6.84, p = 0.006) and OS (HR 4.11, 95% CI 1.44–11.74, p = 0.008). No impact was observed with capecitabine monotherapy, 5‐FU, or FOLFOX. Concomitant PPI use is common in Australian patients with Stage III colon cancer. While formal interaction testing did not reach statistical significance, PPI use was associated with inferior survival outcomes in high‐risk patients receiving CAPOX.


  • Impact of BRAF Gene Mutation in Nonmetastatic Colorectal Cancer on Disease Progression and Survival Outcomes

    by Caroline Lum, Harrison Boka, Mohammad Asghari‐Jafarabadi, Shehara Mendis, Lauren Cohen, Helen E. Abud, Rebekah M. Engel, Paul J. McMurrick

    Background and Aim: Colorectal cancer (CRC) is a major global health concern, with molecular and histopathological subtypes influencing disease progression. Mutations in the v‐Raf murine sarcoma viral oncogene homolog B (BRAF) gene, particularly the V600E variant, define a subset associated with aggressive features. The impact of BRAF mutations on early‐stage CRC prognosis and their interaction with mismatch repair (MMR) status remains less characterized. Methods: We conducted a retrospective analysis of prospectively collected data from two tertiary institutions on Stage II–III CRC patients. BRAF/MMR subgroups were defined (BRAFmut/pMMR, BRAFmut/dMMR, BRAFwt/pMMR, and BRAFwt/dMMR). Associations with patient/tumor characteristics, adjuvant treatment, and long‐term outcomes were assessed. Univariate and multivariate analyses were used to evaluate disease recurrence and mortality. Results: Of 157 eligible patients, univariate analyses indicated poorer outcomes for those with pMMR CRC. Multivariate analysis examining disease recurrence and death highlights that pMMR patients perform worse, but significantly, this analysis revealed that BRAFmut is a significant predictor of mortality in the nonmetastatic setting, irrespective of MMR status. Conclusions: Nonmetastatic BRAFmut CRC carries a dismal prognosis, irrespective of MMR status. Routine testing for BRAF V600E mutation alongside MMR assessment is advocated to inform personalized management, potentially impacting surveillance, adjuvant therapy decisions, and eligibility for targeted therapies.


  • Early onset pancreatic cancer—exploring contemporary treatment and outcomes using real-world data

    by Shehara Mendis, Lara Lipton, Yat Hang To, Sumitra Ananda, Michael Michael, Sue-Anne McLachlan, Benjamin Thomson, Benjamin Loveday, Brett Knowles, Adrian Fox, et al.

    Background Pancreatic cancer incidence is increasing in younger populations. Differences between early onset pancreatic cancer (EOPC) and later onset pancreatic cancer (LOPC), and how these should inform management warrant exploration in the contemporary setting. Methods A prospectively collected multi-site dataset on consecutive pancreatic adenocarcinoma patients was interrogated. Patient, tumour, treatment, and outcome data were extracted for EOPC (≤50 years old) vs LOPC (>50 years old). Results Of 1683 patients diagnosed between 2016 and 2022, 112 (6.7%) were EOPC. EOPC more frequently had the tail of pancreas tumours, earlier stage disease, surgical resection, and trended towards increased receipt of chemotherapy in the curative setting compared to LOPC. EOPC more frequently received 1st line chemotherapy, 2nd line chemotherapy, and chemoradiotherapy than LOPC in the palliative setting. Recurrence-free survival was improved for the tail of pancreas EOPC vs LOPC in the resected setting; overall survival was superior for EOPC compared to LOPC across the resected, locally advanced unresectable and metastatic settings. Conclusions EOPC remains a small proportion of pancreatic cancer diagnoses. The more favourable outcomes in EOPC suggest these younger patients are overall deriving benefits from increased treatment in the curative setting and increased therapy in the palliative setting.


  • Open Access

    Data from Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types

    by James T. Topham, Emma Titmuss, Erin D. Pleasance, Laura M. Williamson, Joanna M. Karasinska, Luka Culibrk, Michael K.C. Lee, Shehara Mendis, Robert E. Denroche, Gun-Ho Jang, et al.

    Next-generation sequencing of solid tumors has revealed variable signatures of immunogenicity across tumors, but underlying molecular characteristics driving such variation are not fully understood. Although expression of endogenous retrovirus (ERV)-containing transcripts can provide a source of tumor-specific neoantigen in some cancer models, associations between ERV levels and immunogenicity across different types of metastatic cancer are not well established. We performed bioinformatics analysis of genomic, transcriptomic, and clinical data across an integrated cohort of 199 patients with metastatic breast, colorectal, and pancreatic ductal adenocarcinoma tumors. Within each cancer type, we identified a subgroup of viral mimicry tumors in which increased ERV levels were coupled with transcriptional signatures of autonomous antiviral response and immunogenicity. In addition, viral mimicry colorectal and pancreatic tumors showed increased expression of DNA demethylation gene TET2. Taken together, these data demonstrate the existence of an ERV-associated viral mimicry phenotype across three distinct metastatic cancer types, while indicating links between ERV abundance, epigenetic dysregulation, and immunogenicity.

  • Open Access

    Supplementary Table 3 from Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types

    by James T. Topham, Emma Titmuss, Erin D. Pleasance, Laura M. Williamson, Joanna M. Karasinska, Luka Culibrk, Michael K.C. Lee, Shehara Mendis, Robert E. Denroche, Gun-Ho Jang, et al.

    Supplemental Table S3 lists gene sets significantly enriched among genes up-regulated in VMP samples.

  • Open Access

    Supplementary table 1 and figures 1-4 from Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types

    by James T. Topham, Emma Titmuss, Erin D. Pleasance, Laura M. Williamson, Joanna M. Karasinska, Luka Culibrk, Michael K.C. Lee, Shehara Mendis, Robert E. Denroche, Gun-Ho Jang, et al.

    Supplemental Table S1 lists clinical characteristics for the study cohort. Figure S1 depicts results of batch correction. Figures S2 and S3 show comparisons between ERV levels and tumor content. Figure S4 shows ERV levels across different biopsy sites.

  • Open Access

    Supplementary Table 5 from Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types

    by James T. Topham, Emma Titmuss, Erin D. Pleasance, Laura M. Williamson, Joanna M. Karasinska, Luka Culibrk, Michael K.C. Lee, Shehara Mendis, Robert E. Denroche, Gun-Ho Jang, et al.

    Supplemental Table S5 lists EGA accession numbers for each sample included in the study.

  • Open Access

    Supplementary table 2 from Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types

    by James T. Topham, Emma Titmuss, Erin D. Pleasance, Laura M. Williamson, Joanna M. Karasinska, Luka Culibrk, Michael K.C. Lee, Shehara Mendis, Robert E. Denroche, Gun-Ho Jang, et al.

    Supplemental Table S2 lists all genes differentially expressed in VMP samples.

  • Open Access

    Data from Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types

    by James T. Topham, Emma Titmuss, Erin D. Pleasance, Laura M. Williamson, Joanna M. Karasinska, Luka Culibrk, Michael K.C. Lee, Shehara Mendis, Robert E. Denroche, Gun-Ho Jang, et al.

    Next-generation sequencing of solid tumors has revealed variable signatures of immunogenicity across tumors, but underlying molecular characteristics driving such variation are not fully understood. Although expression of endogenous retrovirus (ERV)-containing transcripts can provide a source of tumor-specific neoantigen in some cancer models, associations between ERV levels and immunogenicity across different types of metastatic cancer are not well established. We performed bioinformatics analysis of genomic, transcriptomic, and clinical data across an integrated cohort of 199 patients with metastatic breast, colorectal, and pancreatic ductal adenocarcinoma tumors. Within each cancer type, we identified a subgroup of viral mimicry tumors in which increased ERV levels were coupled with transcriptional signatures of autonomous antiviral response and immunogenicity. In addition, viral mimicry colorectal and pancreatic tumors showed increased expression of DNA demethylation gene TET2. Taken together, these data demonstrate the existence of an ERV-associated viral mimicry phenotype across three distinct metastatic cancer types, while indicating links between ERV abundance, epigenetic dysregulation, and immunogenicity.

  • Open Access

    Supplementary table 1 and figures 1-4 from Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types

    by James T. Topham, Emma Titmuss, Erin D. Pleasance, Laura M. Williamson, Joanna M. Karasinska, Luka Culibrk, Michael K.C. Lee, Shehara Mendis, Robert E. Denroche, Gun-Ho Jang, et al.

    Supplemental Table S1 lists clinical characteristics for the study cohort. Figure S1 depicts results of batch correction. Figures S2 and S3 show comparisons between ERV levels and tumor content. Figure S4 shows ERV levels across different biopsy sites.